Inventor · disambiguated record
Jonathan G. Drachman
Also filed as: DRACHMAN JONATHAN · DRACHMAN JONATHAN G · DRACHMAN JONATHAN GREGOR
2 granted patents·9 pending applications·119 citations·filing 2006–2023
70Inventor score
Top patents by PatentIndex Score
11 records- 0195US8663642B2Anti-CD70 antibody-drug conjugates and their use for the treatment and prevention of cancer and immune disordersLAW CHE-LEUNG·Filed 2010·Granted Mar 4, 2014·44 cites·21 claims
- 0294US7695716B2Methods of treating neoplastic, autoimmune and inflammatory diseasesSEATTLE GENETICS INC·Filed 2008·Granted Apr 13, 2010·75 cites·38 claims
- 0367US2024076402A1Humanized anti-liv1 antibodies for the treatment of breast cancerSEAGEN INC·Filed 2023·Application pending·0 cites
- 0464US2008025989A1Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disordersSEATTLE GENETICS INC·Filed 2007·Application pending·0 cites
- 0556US2020283540A1Humanized anti-liv1 antibodies for the treatment of breast cancerSEATTLE GENETICS INC·Filed 2018·Application pending·0 cites
- 0656US2011038856A1Methods of treating neoplastic, autoimmune and inflammatory diseasesSEATTLE GENETICS INC·Filed 2007·Application pending·0 cites
- 0749US2023331858A1Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitorNEOLEUKIN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 0848US2023025600A1Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteinsAGENSYS INC·Filed 2020·Application pending·0 cites
- 0947US2022370563A1Methods of administration of il-2 receptor agonistsNEOLEUKIN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1044US2010215653A1Methods of treating neoplastic, autoimmune and inflammatory diseasesSEATTLE GENETICS INC·Filed 2010·Application pending·0 cites
- 1141US2009304687A1Methods of using cd40 binding agentsSEATTLE GENETICS INC·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jonathan G. Drachman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →